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Abstract: Serotonin (5-HT) is a monoamine neurotransmitter and plays important roles  
in several of the human body’s systems. Known as a primary target for psychoactive drug 
development, the 5-HT transporter (5-HTT, SERT) plays a critical role in the regulation of 
serotonergic function by reuptaking 5-HT. The allelic variation of 5-HTT expression is 
caused  by  functional  gene  promoter  polymorphism  with  two  principal  variant  alleles,  
5-HTT  gene-linked  polymorphic  region  (5-HTTLPR).  It  has  been  demonstrated  that  
5-HTTLPR is associated with numerous neuropsychiatric disorders. The functional roles of 
5-HTTLPR have been reported in human choriocarcinoma (JAR), lymphoblast and raphe 
cells.  To  date,  the  significance  of  5-HTTLPR  in  gastrointestinal  tract-derived  cells  has 
never been elucidated. Thus, the impact of 5-HTTLPR on 5-HTT transcription was studied 
in SW480 human colon carcinoma cells, which were shown to express 5-HTT. We found 
42-bp fragment in long (L) allele as compared to short (S) allele, and this allelic difference 
resulted in 2-fold higher transcriptional efficiency of L allele (P < 0.05) as demonstrated 
using a functional reporter gene assay. Nevertheless, the transcriptional effect of estrogen 
and glucocorticoid on 5-HTT expression via 5-HTTLPR was not found in this cell line. 
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Our  study  was  the  first  to  demonstrate  the  molecular  role  of  this  allelic  variation  in 
gastrointestinal tract cells. 
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1. Introduction 
Serotonin  (5-Hydroxytryptamine,  5-HT)  is  most  frequently  thought  of  as  a  monoamine 
neurotransmitter  in  the  central  nervous  system  (CNS).  In  fact,  it  plays  numerous  critical  roles  in 
several human body’s systems, especially gastrointestinal (GI) system [1,2]. About 95% of the body’s 
5-HT  resides  in  the  gut.  The  predominant  site  of  5-HT  synthesis,  storage,  and  release  is  the 
enterochromaffin (EC) cells of the intestinal mucosa, and virtually all of the 5-HT in the blood is 
derived from the GI tract [3]. Within the GI system, 5-HT plays a critical role as a paracrine messenger 
and a neurotransmitter in the regulation of GI motility, secretion [3,4] and sensation [5,6] via secretion 
from  EC  cells.  These  particular  cells  function  as  sensory  transducers  in  response  to  mechanical 
pressure  and  nutrients  such  as  glucose  and  short-chain  fatty  acids,  and  secrete  5-HT  from  their 
basolateral surfaces into the wall of the bowel [2]. Then, the released 5-HT acts as a crucial signaling 
molecule, which initiates responses as diverse as nausea, vomiting, peristaltic and secretory reflexes [7] 
through a variety of 5-HT receptors located on the mucosal processes of both intrinsic and extrinsic 
primary afferent neurons that project to the lamina propria. However, mucosal 5-HT molecules have to 
be very rapidly metabolized, mainly as a result of the activity of monoamine oxidase by an inactivating 
mechanism,  a  transporter-mediated  uptake,  in  the  gut  because  circulating  free  5-HT  is  toxic  and 
passive diffusion is too slow to prevent the accumulation of 5-HT in contact with its receptors [8]. This 
process is mediated by the similar transporter utilized by serotonergic neurons, known as the 5-HT 
transporter (5-HTT or SERT) which is present both in the mucosa and in nerves of the enteric nervous 
system (ENS). 
The human 5-HTT is a highly selective sodium- and chloride-dependent transporter, expressed in 
brain, blood and GI cells, and encoded by a single gene (SLC6A4), which is composed of 14 exons 
spanning 37.8 kb [9] on chromosome 17q11.2 [10]. A polymorphism has been identified in the region 
for transcriptional control of SLC6A4, termed the 5-HTT gene-linked polymorphic region (5-HTTLPR), 
which consists of different lengths of the repetitive GC-rich sequence containing 20–23 bp located 
approximately 1.4 kb upstream of the 5-HTT gene transcription site [9]. The deletion/insertion in the 
5-HTTLPR creates two predominant variant alleles, a short (S) allele and a long (L) allele which has 
14- and 16-repeat elements, respectively. As far as the significance of this particular allelic variation is 
concerned, 5-HTTLPR has been demonstrated to affect the expression and function of 5-HTT. Studies 
using  reporter  gene  assays  revealed  that  the  S  variant  reduced  transcriptional  efficiencies  of  the 
SLC6A4 in a human placental choriocarcinoma cell line (JAR) [11], lymphoblast cell lines [12] and in 
the raphe nucleus-derived cell line (RN46A) [13]. In agreement with the reporter gene assays, higher 
5-HTT  mRNA  levels  and  higher  rates  of  5-HT  uptake  were  observed  in  lymphoblasts  of  L/L 
homozygotes compared to those containing at least one copy of the S allele [12]. The L variant was Int. J. Mol. Sci. 2011, 12  6621 
 
 
also correlated with higher rates (Vmax) of 5-HT uptake in platelets [14], suggesting that the S variant 
may act as a dominant allele. In addition, the alteration of the serotonergic activity has been shown to 
be involved in several diseases. Although the results of these studies have been somewhat inconsistent, 
this  polymorphism  has  been  reported  to  associate  with  not  only  psychiatric  disorders  such  as 
depression [15–18], schizophrenia [19], anxiety [20], suicide [21,22] and autism [23], but also certain 
GI syndromes such as irritable bowel syndrome (IBS) [24,25]. Thus, 5-HTT has also shown itself to be 
an effective pharmacological target in the treatment of IBS [26,27]. 
While  the  previous  studies  provided  evidence  for  allele-dependent  differential  5-HTT  promoter 
activity in cells from blood, placenta and brain, information regarding the significance of 5-HTTLPR 
in cells originated from the GI tracts has never been elucidated. Therefore, the impact of 5-HTTLPR 
on 5-HTT transcription was studied in human epithelial-like colon carcinoma cells using functional 
reporter gene assays in this study. We also intended to investigate the effects of steroid hormones 
including glucocorticoid and estrogen on 5-HTT expression because the binding of these hormones  
to  their  receptors  can  trigger  conformational  changes  enabling  the  receptor  dimer  to  interact  with  
DNA-associated  regulatory  elements.  The  physiological  response  is  induced  by  activation  or 
deactivation of an adjoining gene promoter which influences transcriptional efficiencies. Recently, it 
has  been  reported  that  5-HTT  expression  is  modulated  by  glucocorticoid  administration  in  the 
placental (JAR) cell line with allele-dependent effects [28]. Besides, few studies have reported the 
relationship between estrogen and 5-HTT. For example, significant decrease in 5-HTT mRNA was 
observed upon estrogen treatment in rhesus macaques [29,30] and rat brain cells [31], but no study 
regarding  the  involvement  of  5-HTTLPR  has  been  performed.  Thus,  we  hypothesized  that  these 
hormonal effects with respect to 5-HTTLPR may be similar in GI tract-derived cells as compared to 
other cell types in the previous studies. In this article, in addition to studying the allele-dependent role 
of 5-HTTLPR in GI cells, we investigated whether 5-HTT expression is modulated by estrogen or 
glucocorticoid administration via 5-HTTLPR in cellular model system. Therefore, prior to reporter gene 
assays, we examined whether mRNA transcripts for 5-HTT, glucocorticoid receptor (GR) and estrogen 
receptor (ER) are expressed in human colon carcinoma cell lines, SW480 and HT-29, using the reverse 
transcription-polymerase chain reaction (RT-PCR) method for evaluating an appropriate cell model. 
2. Results and Discussion 
2.1. 5-HTTLPR Different Sequence and Transcription Factor Binding Sites 
PCR amplification products were generated with primers flanking the 5-HTTLPR using different 
genomic  DNA  templates  and  analyzed  by  DNA  sequencing.  The  484/528-bp  DNA  fragments  for  
short (S) and long (L) alleles were shown as a result of PCR (Figure 1). In this study, we found an 
insertion of 42-bp (5′-CCTTC CAGCA TCCCC CTGCA CCCCC AGCAT CCCCC CTGCA GC-3′) 
fragment in L allele as compared to S allele. When analyzed using Jotan Hein Method of MegAlign 
program,  this  GC-rich  sequence  revealed  87.8%  similarity  to  the  previously  described  44-bp  
fragment  [11].  Additionally,  it  contains  numerous  potential  binding  sites  for  several  transcription 
factors  including  TFII-1,  STAT4,  c-Ets-1,  Elk-1,  PEA3,  GR-alpha,  XBP-1,  RXR-alpha  and  EBF 
(Figure 2) as analyzed using the Promo program [32,33]. Int. J. Mol. Sci. 2011, 12  6622 
 
 
Figure  1.  Genotyping  of  5-HTT  using  PCR  and  subjected  to  3%  agarose  gel 
electrophoresis.  From  left  to  right,  100  bp  DNA  molecular  weight  marker  (M);  S/S 
homozygote (484 bp, 14 repeats), L/L homozygote (528 bp, 16 repeats). 
 
Figure 2. Map of potential transcription factor binding sites on 42-bp 5-HTTLPR fragment 
analyzed using the Promo program. 
 
2.2. Expression of 5-HTT, GRα and ERα in Human Colon Carcinoma Cells 
We evaluated two human colon carcinoma cell lines, SW480 and HT-29, using RT-PCR approach 
in order to select the most suitable in vitro model. All mRNA transcripts examined were found to 
express in the two cell lines, but GRα transcripts were not detected in HT-29 (Figure 3). Therefore, 
SW480 was a cellular model chosen in this study as both estrogen and glucocorticoid receptors were 
expressed, indicating that this cell line could be employed for testing the effects of respective steroid 
hormones via 5-HTT. 
2.3. Allelic-Specific Transcriptional Activity in Human Colon Carcinoma Cells 
The  organization  of  the  human  5-HTT  gene  promoter  and  map  of  three  5-HTTLPR  luciferase 
reporter  gene  constructs,  p5HTT[L860]Luc  (−736  to  +124  bp),  p5HTT[S]  Luc  and  p5HTT[L]Luc 
(−1796 to +124 bp) (GenBank accession no. X76753), were depicted (Figure 4). It was evident that the 
5-HTT gene promoter contained a TATA-like motif and a number of potential transcription factor 
recognition sites. The 5-HTTLPR is the polymorphic tandem repeat of the 5-HTT gene promoter, 
defined by a length variation of a GC-rich repetitive sequence with 21-bp repeat elements found in this 
study. Using three different constructs for reporter gene assays, allelic-specific transcriptional activity 
of 5-HTTLPR was analyzed in SW480 cells, which were shown to express the human 5-HTT. As 
shown in Figure 5, we found the luciferase activity of the long variant promoter construct (p5HTT[L]Luc) 
was  about  two-fold  greater  than  that  of  the  short  variant  (p5HTT[S]Luc),  and  difference  was 
statistically  significant  (P  <  0.001  by  Student’s  t-test).  The  two  shorter  constructs  possessed Int. J. Mol. Sci. 2011, 12  6623 
 
 
comparable  level  of  luciferase  activities  regardless  of  the  presence  or  absence  of  short  variant  
of 5-HTTLPR. 
Figure  3.  Expression  of  mRNA  transcripts  for  (A)  β-actin;  (B)  5-HTT;  (C)  ERα;  and  
(D)  GRα  in  human  colon  carcinoma  cells,  SW480  (Lane  1)  and  HT-29  (Lane  2) 
determined  using  RT-PCR.  M  represents  the  100  bp  DNA  molecular  weight  marker. 
Arrows indicate positions of the specific bands of RT-PCR products. 
 
Figure 4. The organization of the human 5-HTT gene promoter and map of 5-HTTLPR 
luciferase reporter gene constructs, p5HTT[S]Luc, p5HTT[L]Luc and p5HTT[L860]Luc. 
The nucleotide sequence of 42-bp length polymorphism is shown. 
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Figure 5. Transcriptional activity of the 5-HTTLPR luciferase reporter gene constructs,  
S, L and no 5-HTTLPR, respectively, in SW480 cells. Data are mean ±S.D. for triplicate 
determinations, *** P < 0.001 by student’s t-test. 
 
2.4. Effect of Steroids on 5-HTT Promoter Activity 
In  addition,  we  also  investigated  whether  the  steroid  hormones,  glucocorticoid  and  estrogen, 
regulate 5-HTT expression by employing the synthetic glucocorticoid dexamethasone, which binds 
specifically to the GR, and β-estradiol, which binds specifically to the ER. SW480 cell line was a 
proper model because it was demonstrated to express not only 5-HTT transcripts, but also transcripts 
for  steroid  hormone  receptors,  GRα  and  ERα.  As  shown  in  Figure  6,  black  and  white  columns 
represent reporter gene activity of the long variant allele p5HTT[L]Luc and the short variant allele 
p5HTT[S]Luc, respectively. No difference was found at 10
−3, 10
−6 and 10
−9 M concentration when 
compared to 0 M dexamethasone or β-estradiol for the same allele. 
Figure 6. Effects of (A) dexamethasone and (B) β-estradiol on 5-HTT promoter activity of 
the 5-HTTLPR luciferase reporter gene constructs, S, L and on 5-HTTLPR, respectively, in 
SW480 cells. Data are mean ± S.D. for triplicate determinations. 
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2.5. Discussion 
5-HT is most commonly thought of as a neurotransmitter in the CNS. However, the predominant 
site of 5-HT synthesis, storage, and release is the EC cells of the intestinal mucosa. EC cells contain 
more than 90% of total 5-HT, which makes GI system the main source of 5-HT in the body. 5-HT 
plays various very important roles in peristaltic and secretory  reflexes  in response to  chemical or 
mechanical stimuli of the gut [7]. 5-HTT plays a critical role in serotonergic neurotransmission that is 
responsible for the reuptake of 5-HT in the mucosa of the bowel, and is a factor that determines 5-HT 
activity.  Additionally,  the  alteration  of  the  serotonergic  activity,  examined  by  genetic  variants  in  
5-HTT gene, especially 5-HTTLPR which has been implicated in several gut diseases, has been shown 
to be involved in many pathological processes such as IBS. In animal model study, 5-HTT knockout 
mice had diarrhea, which was associated with increased colonic motility and excretion of water in the 
stool [34]. Moreover, diarrhea predominant IBS (D-IBS) was associated with significant reduction in 
human mucosal 5-HT [35], but increased in plasma concentrations [36], implicating that 5-HTT levels 
were reduced consistent with genetic results. It has been reported that S/S genotype was significantly 
associated with D-IBS [25,37]. 
At  present,  there  is  no  molecular  information  regarding  the  impact  of  5-HTTLPR  on  5-HTT 
transcription  in  cells  originated  from  the  GI  tract,  although  certain  studies  were  conducted  using  
cells from blood, placenta and brain. In our study, we found the L allele containing 16 repeats has 
approximately 2-fold higher transcriptional activity of 5-HTT gene than S allele containing 14 repeats 
in SW480 cells, indicating that this region contains a positive transcriptional element or the insertion 
of the two extra repeats changes the binding profile of transcription factor by altering the physical 
distance. Our finding is in agreement with other investigations using JAR [11], lymphoblasts [12] and 
RN46A [13] with about 2- to 3-fold higher activity found in L than S variant. Taken together with 
other previous findings into account, the regulatory difference between the two alleles seems to be 
cell-specific; however, we could not summarize that this occurred only in 5-HTT expressed cells in 
this study because, after screening about 10 cell lines using RT-PCR, we could not find human cell 
lines not expressing 5-HTT. Rhesus monkeys have an analogous 5’-flanking region length variant 
generated by 21-bp insertion or deletion (rh5-HTTLPR), whereas rodents lack such length variants [9], 
indicating that 5-HTTLPR which is only present in humans and higher non-human primates. In this 
investigation, the two shorter constructs possessed comparable level of luciferase activities regardless 
of the presence or absence of short variant of 5-HTTLPR, suggesting that basal promoter activity could 
be obtained without the short variant of 5-HTTLPR. 
In  agreement  with  the  reporter  gene  assays,  lymphoblasts  of  L/L  homozygotes  have  been 
demonstrated to  yield higher 5-HTT mRNA levels than those containing at least one copy of the  
S allele [12]. Nevertheless, 5-HTT mRNA levels in human pons were not well correlated with the  
5-HTTLPR alleles [38]. This inconsistency may be due to not only cell-type specificity, but also other 
complex processes in regulating the gene expression, such as epigenetics. For instance, the methylation 
of an upstream CpG island has been shown to be associated with 5-HTT mRNA levels as the L allele 
having lesser amounts of methylation than those of the S allele [39]. This effect was evaluated in 
lymphoblast cell line, and this may not necessary be true in other models. Moreover, these functional 
promoter assays could theoretically give spurious results because of not representing a closed loop of Int. J. Mol. Sci. 2011, 12  6626 
 
 
gene regulation. Effects in luciferase promoter assays generally tend to be large due to the lack of 
negative feedback, as the product of the reaction, the fluorescent protein luciferase, does not activate 
the negative feedback loops limiting its transcription in the way the protein product 5-HTT would. It is 
therefore important to look also at physiological cellular systems where these feedback mechanisms 
operate.  However,  investigation  on  5-HTT  protein  expression  in  the  cellular  system,  as  uptake 
measurement or inhibitor binding, is possible, but using the radioactive method is required.  
In this study, we also tested whether 5-HTT expression could be regulated by the effect of steroid 
hormones, glucocorticoid and estrogen, via 5-HTTLPR. However, the transcriptional effect of both 
steroids was not found in SW480 cells. This result was inconsistent with the previous finding [28]  
that  demonstrated  the  acute  glucocorticoid-dependent  increased  5-HTT  expression  in  JAR  as  an  
allele-specific  promoter  activation,  suggesting  that  the  glucocorticoid  effect  may  be  cell-specific. 
Besides, this result might account for the missing sequence of about 400 bp, which was not included in 
previous  studies  [13,40].  Moreover,  a  novel  transcript  of  5-HTT  based  on  alternate  promoter  and 
transcriptional start site has been revealed to predominate in intestinal mucosa, which differs from 
previously  reported  transcripts  [41].  This  particular  finding  reflects  a  more  complex  picture  of 
regulation of 5-HTT gene expression, thus highlighting the difference between GI and brain in this 
regard.  Therefore,  the  steroid  response  element  of  5-HTT  gene  in  GI  may  be  located  in  another 
promoter  region  since  the  recent  study  suggests  that  the  putative  EGF-responsive  elements  are 
presented  in  different  regions  of  the  two  alternate  promoters  [42].  It  is  worth  noting  that  herbal 
compounds, berberine and evodiamine, could influence the expression of 5-HTT via 5-HTTLPR [43], 
thus suggesting the potential therapeutic applications of such natural compounds.  
Estrogen, the main sex hormone in women essential for the menstrual cycle, is another steroid also 
involved in serotonergic system. Both the neurotransmitter 5-HT and the ovarian steroid estrogen have 
been implicated in the modulation of mood and cognition, although the nature of their relationship has 
not  been  fully  elucidated.  Research  using  ovariectomized  animals  has  identified  estrogen-induced 
changes in 5-HT transmission, binding and metabolism in brain regions implicated in the regulation of 
affect and cognition [44]. Certain studies have shown the existence of ERβ mRNA and protein in 
serotonergic neurons [45,46]. Immunocytochemical localization in the mouse and rat brain also found 
ERβ-labeled cells, but slight ERα-labeled cells in neurons of the raphe nuclei [47,48], supporting that 
ERβ is more closely associated with 5-HT regulatory system than ERα. Although we were not able  
to detect ERβ transcripts in this study, SW480 and HT-29 were epithelial-like cells from intestinal 
mucosa that have been reported to express ERβ in both colon cancer and normal colon tissues [49,50]. 
Also, β-estradiol employed in this report is a substance for binding to both ERα and ERβ. 
Acute estradiol administration in ovariectomized rats increases 5-HT and its metabolite (5-HIAA) 
in various brain regions as dorsal raphe and striatum [51,52], suggesting an increase in 5-HT turnover. 
In  addition,  there  are  studies  establishing  a  relationship  between  estrogen  and  5-HTT,  but  there  
often  appear  to  be  conflicting  results  regarding  estrogen  effects.  Certain  studies  have  shown  that 
estrogen administration following ovariectomy increases 5-HT uptake [53] and the number of 5-HTT  
binding sites [54], whereas some have shown the reduction of 5-HT uptake [31] and 5-HTT mRNA 
expression [29,30] after estrogen treatment and a low estrogen state increases 5-HTT activity [55]. 
Estrogen  has  been  shown  to  decrease  mRNA  [56]  and  the  activity  of  monoamine  oxidase  [57], 
including increased 5-HT2A receptor mRNA [58,59]. Int. J. Mol. Sci. 2011, 12  6627 
 
 
Estrogen is mostly used in hormone replacement therapy (ERT) that is given to postmenopausal or 
surgically  menopausal  women  in  order  to  prevent  osteoporosis  and  to  treat  the  symptoms  of 
menopause such as hot flashes and vaginal dryness. On the other hand, there are certain health risks for 
long time or overdose use including breast cancer and heart disease. Therefore, further investigations 
on their molecular interactions in CNS and GI system are indispensable. Also molecular understanding 
of the relationship between estrogen and serotonin will guide to new drug development or other novel 
therapeutic approaches in order to increase treatment efficiency and decrease side effects. 
3. Experimental Section 
3.1. PCR Analysis of the 5-HTT Gene-Linked Polymorphic Region 
DNA was isolated from whole blood using FlexiGene DNA kit (Qiagen, Hilden, Germany), and 
subsequently  screened  by  polymerase  chain  reaction  (PCR)  using  Taq  PCRx  DNA  polymerase 
(Invitrogen, Carlsbad, CA, USA) and primers specific to the 5-HTTLPR [11] as shown in Table 1. The 
product was generated as a 484/528 bp fragment for short (S) and long (L) alleles, respectively. PCR 
amplification was carried out in a final volume of 25 µL consisting of genomic DNA as a template,  
0.2 mM each deoxyribonucleotide, 0.2 µM of sense and antisense primers, 2× PCRx enhancer solution, 
20 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgSO4 and 1.25 U of Taq DNA polymerase. After 
denaturing for 2 min at 95 °C, the desired DNA fragment was amplified for 35 cycles of 95 °C for 30 s, 
60 °C for 30 s, and 68 °C for 1 min with the final extension at 68 °C for 10 min. 
Table  1.  Oligonucleotide  sequences  and  their  locations  used  to  generate  allelic 
transcriptional fragments of the 5-HTT gene. 
Name  Oligonucleotide sequence 
a (5′→3′)  Position 
b,*  Construct 
5-HTTLPR-F  GGCGTTGCCGCTCTGAATTGC  −1416/−1397   
5-HTTLPR-R  GAGGGACTGAGCTGGACAACCAC  −910/−889   
−1796F/KpnI  CAAAGGTACCGTTGCCGCTCTGAATGCCAG  −1796/−1767  ph5HTT[L]Luc 
      ph5HTT[S]Luc 
−736F/KpnI  CAAGGTACCGAATTCCTGGGCTCAAGCAATCCT  −736/−704  ph5HTT[L860]Luc 
+124R/HindIII  CCGAAGCTTGAAACGTGGGTTCGAGGCGGAGAG  +124/+156   
a The KpnI and HindIII sites are indicated as underlined and double-underlined, respectively; 
b Nucleotide 
positions relative to the transcription start site (+1) of the SERT gene; *
 GenBank accession no. X76753. 
3.2. DNA Sequencing 
The  extension  products  from  PCR  analysis  step  were  subsequently  purified  from  excess 
unincorporated dye terminators by ethanol precipitation according to the manufacturer’s instructions 
(ABI Sequencing kit, ABI, Foster City, CA, USA) and subjected to sequence analysis by the ABI 
Prism 310 Genetic Analyzer (ABI). Int. J. Mol. Sci. 2011, 12  6628 
 
 
3.3. Transcription Factor Binding Site Analysis 
The sequencing data of S allele was compared to L allele by MegAlign program (DNASTAR, 
Madison, WI, USA). Transcription factor binding sites of the different sequences were analyzed by 
Promo program [32,33]. 
3.4. Plasmid Constructions 
In  this  study,  plasmid  constructions  for  reporter  gene  assays  were  carried  out  as  previously 
described  [60,61].  Briefly,  we  produced  three  reporter  plasmid  constructs  containing  S,  L  and  no  
5-HTTLPR DNA fragments using two forward primers, −1796F/KpnI and −736F/KpnI, and reverse 
primer, +124R/HindIII, which are listed in Table 1. All fragments were amplified using Taq PCRx 
DNA  polymerase  (Invitrogen),  and  ligated  into  the  promoterless  luciferase  expression  vector,  
pGL3-Basic (a generous gift from Dr. Robert K. Yu, Institute of Molecular Medicine and Genetics, 
Medical College of Georgia, Georgia Health Sciences University, GA, USA) with KpnI and HindIII 
enzyme sites (New England Biolabs, Ipswich, MA, USA). All plasmid were verified by restriction 
mapping and DNA sequencing. 
3.5. Cell Culture 
The  SW480  and  HT-29  human  colon  carcinoma  cell  lines  were  kindly  provided  by  
Dr. Apiwat Mutirangura (Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand) and  
Dr.  Weerah  Wongkham  (Faculty  of  Science,  Chiang  Mai  University,  Chiang  Mai,  Thailand), 
respectively.  They  were  cultured  in  Dulbecco’s  modified  Eagle’s  medium  (DMEM)  supplemented 
with 10% fetal bovine serum (FBS), and cells were maintained at 37 °C in a humidified atmosphere at 
5% CO2. 
3.6. Total RNA Extraction and RT-PCR Reaction 
Total cellular RNA was isolated from SW480 and HT-29 cells using Trizol reagent (Invitrogen) 
following a procedure given by the manufacturer. The amount of RNA was determined by absorbance 
at  260  nm.  Prior  to  RT-PCR  reaction,  about  1  µg  of  the  total  RNA  was  treated  with  10
−5  U 
deoxyribonuclease  (DNase)  I  (Invitrogen)  for  15  min  at  25  °C.  RT-PCR  was  performed  using 
SuperScript™ III One-Step RT-PCR system with Platinum Taq DNA polymerase (Invitrogen) and 
specific primers listed in Table 2 for 5-HTT transcripts [62], GRα transcripts [63], ERα transcripts [64] 
and  either  glyceraldehyde  3-phosphate  dehydrogenase  (GAPDH)  [65]  or  β-actin  [66]  transcripts  
as positive controls. The reaction was performed in a final volume of 25 µL, containing about 100 ng 
of  DNase  I-treated  RNA,  0.4  µM  of  sense  and  antisense  primers,  1×  reaction  mix  (containing  
0.2 mM dNTP, 1.6 mM MgSO4) and SuperScript™ III RT/ Platinum Taq mix. cDNA synthesis was 
carried  out  at  55  °C  for  30  min.  After  initial  denaturation  for  2  min  at  95  °C,  the  desired  DNA 
fragment was amplified for 40 cycles of 95 °C for 30 s, annealing for 30 s at 60 °C for 5-HTT, 52 °C 
for GRα, 58 °C for ERα, GAPDH and β-actin, and 68 °C for 2 min with the final extension at 68 °C 
for 10 min. Int. J. Mol. Sci. 2011, 12  6629 
 
 
Table 2. Specific oligonucleotide primers and expected sizes of RT-PCR products with 
each primer pair. 
Name  Oligonucleotide sequence (5′→3′) 
Product Length 
(bp) 
SERT-sense  CATCTGGAAAGGCGTCAAG  319 
SERT-antisense  CGAAACGAAGCTCGTCATG   
GRα-sense  CTTACTGCTTCTCTCTTCAGTTCCT  204 
GRα-antisense  GCAATAGTTAAGGAGATTTTCAACC   
ERα-sense  TATGGGGTCTGGTCCTGTGA  334 
ERα-antisense  GGGCGGGGCTATTCTTCTTA   
GAPDH-sense  GAAGGTGAAGGTCGGAGTC  226 
GAPDH-antisense  GAAGATGGTGATGGGATTTC   
β-actin-sense  ACGGGTCACCCACACTGTGC  656 
β-actin-antisense  CTAGAAGCATTTGCGGTGGACGATG   
3.7. Transient Transfection and Luciferase Reporter Gene Assay 
Transient  transfections  were  performed  using  Lipofectamine™  2000  (Invitrogen)  following  a 
procedure described by the manufacturer. Briefly, cultured SW480 cells at about 90% confluence in a 
ninety six-well plate were co-transfected with 0.2 µg of each reporter plasmid construct and 0.02 µg of 
the pRL-CMV vector (a generous gift from Dr. Robert K. Yu), which expresses Renilla luciferase 
under the control of the CMV promoter, to monitor the transfection efficiency. The cultured medium 
was  changed  in  the  following  day,  and  cells  were  analyzed  for  the  firefly  and  Renilla  luciferase 
activities after an additional 24 h in culture. Alternatively, after transfection 24 h, either dexamethasone 
or β-estradiol (Sigma, St. Louis, MO, USA) was added in concentrations 10
−3, 10
−6 and 10
−9 M. After 
an additional 24 h in culture, cells were analyzed for the firefly and Renilla luciferase acivities using 
Dual-Glo™  luciferase  assay  system  (Promega,  Madison,  WI,  USA)  following  the  manufacturer’s 
instructions, and chemiluminescence was read using a VICTOR
3 luminometer (PerkinElmer, Waltham, 
MA,  USA).  In  each  transfection  experiment,  untransfected  cells  were  included  as  controls  for  a 
background level of firefly and Renilla luciferase. The pGL3-Basic vector was also transfected in 
parallel as a negative control. 
3.8. Statistical Analysis 
The  firefly  luciferase  activities  were  normalized  to  Renilla  luciferase  activities.  Triplicate 
transfections were performed in each experiment. Luciferase levels were reported as fold elevation in 
activity over that seen in transfections with the promoterless pGL3-Basic vector. The data represented 
the  mean  ±  S.D.  of  three  independent  experiments  and  were  analyzed  by  the  Student’s  t-test. 
Differences at P < 0.05 were regarded as significant. 
4. Conclusions 
In this study, we discovered a differential regulation of 5-HTT expression by 5-HTTLPR in human 
cell line derived from the GI tract. This finding is in agreement with studies conducted using other cell Int. J. Mol. Sci. 2011, 12  6630 
 
 
lines including placental cells, lymphocytes and neuronal cells. Nevertheless, investigation using cells 
with no 5-HTT expression should be conducted to witness if this particular differential regulation by  
5-HTTLPR is cell-specific. In addition, measurement of serotonin content or 5-HTT level actually 
present  in  cells  is  recommended  to  experimentally  confirm  the  serotonin  reuptake  mechanism. 
Unfortunately,  we  did  not  observe  an  effect  of  glucocorticoid  and  estrogen  regulating  the  5-HTT 
expression  in  conjunction  with  these  allelic  variants.  However,  it  is  interesting  to  investigate  the 
molecular  interactions  between  estrogen  and  serotonin  because  their  interactions  and  related 
mechanisms  have  not  been  extensively  elucidated  to  date.  The  42-pb  insertion/deletion  leading  to  
5-HTTLPR  discovered  in  this  study  is  different  from  other  studies  using  genomic  DNA  samples 
isolated  from  Caucasian  subjects.  As  far  as  disease  susceptibility  genes  and  pharmacogenomics  
are  concerned  in  this  post-genomic  era,  studies  performed  using  individual  ethnic  samples  are  of  
critical importance. 
Acknowledgments 
This work was financially supported by a new researcher grant from the Thailand Research Fund 
(TRF)-the Commission on Higher Education (CHE), a grant for development of new faculty staffs, 
Ratchadaphiseksomphot Endowment Fund, Chulalongkorn University, a graduate thesis grant from 
Graduate School, Chulalongkorn University and the Chulalongkorn University Centenary Academic 
Development  Project.  AP  was  party  supported  by  a  graduate  scholarship  and  a  teaching  assistant 
fellowship  from  the  Faculty  of  Allied  Health  Sciences,  Chulalongkorn  University.  The  authors 
gratefully acknowledge the generous gifts of the SW480 cell line from Apiwat Mutirangura, the HT-29 
cell line from Weerah Wongkham, and plasmid vectors from Robert K. Yu. 
References 
1.  Gershon, M.D. Review article: Roles played by 5-hydroxytryptamine in the physiology of the 
bowel. Aliment. Pharmacol. Ther. 1999, 13, 15–30. 
2.  Gershon, M.D. Plasticity in serotonin control mechanisms in the gut. Curr. Opin. Pharmacol. 
2003, 3, 600–607. 
3.  Kim,  D.K.;  Lim,  S.W.;  Lee,  S.;  Sohn,  S.E.;  Kim,  S.;  Hahn,  C.G.;  Carroll,  B.J.  Serotonin 
transporter gene polymorphism and antidepressant response. Neuroreport 2000, 11, 215–219. 
4.  Ormsbee,  H.S.,  III;  Fondacaro,  J.D.  Action  of  serotonin  on  the  gastrointestinal  tract.  
Proc. Soc. Exp. Biol. Med. 1985, 178, 333–338. 
5.  Camilleri, M. Serotonergic modulation of visceral sensation: Lower gut. Gut 2002, 51, i81–i86. 
6.  Tack, J.; Sarnelli, G. Serotonergic modulation of visceral sensation: Upper gastrointestinal tract. 
Gut 2002, 51, i77–i80. 
7.  Martel,  F.  Recent  advances  on  the  importance  of  the  serotonin  transporter  SERT  in  the  rat 
intestine. Pharmacol. Res. 2006, 54, 73–76. 
8.  Gershon,  M.D.  Serotonin  receptors  and  transporters—roles  in  normal  and  abnormal 
gastrointestinal motility. Aliment. Pharmacol. Ther. 2004, 20, 3–14. 
9.  Murphy,  D.L.;  Lerner,  A.;  Rudnick,  G.;  Lesch,  K.P.  Serotonin  transporter:  Gene,  genetic 
disorders, and pharmacogenetics. Mol. Interv. 2004, 4, 109–123. Int. J. Mol. Sci. 2011, 12  6631 
 
 
10.  Ramamoorthy, S.; Bauman, A.L.; Moore, K.R.; Han, H.; Yang-Feng, T.; Chang, A.S.; Ganapathy, V.; 
Blakely, R.D. Antidepressant- and cocaine-sensitive human serotonin transporter: Molecular cloning, 
expression, and chromosomal localization. Proc. Natl. Acad. Sci. USA 1993, 90, 2542–2546. 
11.  Heils, A.; Teufel, A.; Petri, S.; Stober, G.; Riederer, P.; Bengel, D.; Lesch, K.P. Allelic variation 
of human serotonin transporter gene expression. J. Neurochem. 1996, 66, 2621–2624. 
12.  Lesch,  K.P.;  Bengel,  D.;  Heils,  A.;  Sabol,  S.Z.;  Greenberg,  B.D.;  Petri,  S.;  Benjamin,  J.;  
Muller,  C.R.;  Hamer,  D.H.;  Murphy,  D.L.  Association  of  anxiety-related  traits  with  a 
polymorphism in the serotonin transporter gene regulatory region. Science 1996, 274, 1527–1531. 
13.  Mortensen,  O.V.;  Thomassen,  M.;  Larsen,  M.B.;  Whittemore,  S.R.;  Wiborg,  O.  Functional 
analysis  of  a  novel  human  serotonin  transporter  gene  promoter  in  immortalized  raphe  cells.  
Mol. Brain Res. 1999, 68, 141–148. 
14.  Greenberg, B.D.; Tolliver, T.J.; Huang, S.J.; Li, Q.; Bengel, D.; Murphy, D.L. Genetic variation 
in the serotonin transporter promoter region affects serotonin uptake in human blood platelets.  
Am. J. Med. Genet. 1999, 88, 83–87. 
15.  Mossner, R.; Schmitt, A.; Syagailo, Y.; Gerlach, M.; Riederer, P.; Lesch, K.P. The serotonin 
transporter in Alzheimer’s and Parkinson’s disease. J. Neural. Transm. Suppl. 2000, 60, 345–350. 
16.  Mossner, R.; Henneberg, A.; Schmitt, A.; Syagailo, Y.V.; Grassle, M.; Hennig, T.; Simantov, R.; 
Gerlach, M.; Riederer,  P.;  Lesch, K.P. Allelic  variation of serotonin transporter  expression is 
associated with depression in Parkinson’s disease. Mol. Psychiatry 2001, 6, 350–352. 
17.  Gonda, X.; Juhasz, G.; Laszik, A.; Rihmer, Z.; Bagdy, G. Subthreshold depression is linked to the 
functional polymorphism of the 5HT transporter gene. J. Affect. Disord. 2005, 87, 291–297. 
18.  Cervilla,  J.A.;  Rivera,  M.;  Molina,  E.;  Torres-Gonzalez,  F.;  Bellon,  J.A.;  Moreno,  B.;  
de Dios Luna, J.; Lorente, J.A.; de Diego-Otero, Y.; King, M.; et al. The 5-HTTLPR s/s genotype 
at the serotonin transporter gene (SLC6A4) increases the risk for depression in a large cohort of 
primary care attendees: The PREDICT-gene study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 
2006, 141, 912–917. 
19.  Dubertret, C.; Hanoun, N.; Ades, J.; Hamon, M.; Gorwood, P. Family-based association study of 
the 5-HT transporter gene and schizophrenia. Int. J. Neuropsychopharmacol. 2005, 8, 87–92. 
20.  You, J.S.; Hu, S.Y.; Chen, B.; Zhang, H.G. Serotonin transporter and tryptophan hydroxylase 
gene  polymorphisms  in  Chinese  patients  with  generalized  anxiety  disorder.  Psychiatr.  Genet. 
2005, 15, 7–11. 
21.  Campi-Azevedo, A.C.; Boson, W.; De Marco, L.; Romano-Silva, M.A.; Correa, H. Association of 
the serotonin transporter promoter polymorphism with suicidal behavior. Mol. Psychiatry 2003, 8, 
899–900. 
22.  Gaysina, D.; Zainullina, A.; Gabdulhakov, R.; Khusnutdinova, E. The serotonin transporter gene: 
Polymorphism and haplotype analysis in Russian suicide attempters. Neuropsychobiology 2006, 
54, 70–74. 
23.  Brune,  C.W.;  Kim,  S.J.;  Salt,  J.;  Leventhal,  B.L.;  Lord,  C.;  Cook,  E.H.,  Jr.  5-HTTLPR  
genotype-specific phenotype in children and adolescents with autism. Am. J. Psychiatry 2006, 163, 
2148–2156. 
24.  Pata,  C.;  Erdal,  M.E.;  Derici,  E.;  Yazar,  A.;  Kanik,  A.;  Ulu,  O.  Serotonin  transporter  gene 
polymorphism in irritable bowel syndrome. Am. J. Gastroenterol. 2002, 97, 1780–1784. Int. J. Mol. Sci. 2011, 12  6632 
 
 
25.  Park,  J.M.;  Choi,  M.G.;  Park,  J.A.;  Oh,  J.H.;  Cho,  Y.K.;  Lee,  I.S.;  Kim,  S.W.;  Choi,  K.Y.;  
Chung,  I.S.  Serotonin  transporter  gene  polymorphism  and  irritable  bowel  syndrome. 
Neurogastroenterol. Motil. 2006, 18, 995–1000. 
26.  Tack, J.; Broekaert, D.; Fischler, B.; Van Oudenhove, L.; Gevers, A.M.; Janssens, J. A controlled 
crossover  study  of  the  selective  serotonin  reuptake  inhibitor  citalopram  in  irritable  bowel 
syndrome. Gut 2006, 55, 1095–103. 
27.  Sato,  M.;  Murakami,  M.  Treatment  for  irritable  bowel  syndrome—psychotropic  drugs, 
antidepressants and so on. Nihon Rinsho 2006, 64, 1495–1500. 
28.  Glatz,  K.;  Mossner,  R.;  Heils,  A.;  Lesch,  K.P.  Glucocorticoid-regulated  human  serotonin 
transporter (5-HTT) expression is modulated by the 5-HTT gene-promotor-linked polymorphic 
region. J. Neurochem. 2003, 86, 1072–1078. 
29.  Pecins-Thompson, M.; Brown, N.A.; Bethea, C.L. Regulation of serotonin re-uptake transporter 
mRNA expression by ovarian steroids in rhesus macaques. Mol. Brain Res. 1998, 53, 120–129. 
30.  Bethea, C.L.; Gundlah, C.; Mirkes, S.J. Ovarian steroid action in the serotonin neural system of 
macaques. Novartis Found Symp. 2000, 230, 112–133. 
31.  Koldzic-Zivanovic, N.; Seitz, P.K.; Watson, C.S.; Cunningham, K.A.; Thomas, M.L. Intracellular 
signaling involved in estrogen regulation of serotonin reuptake. Mol. Cell. Endocrinol. 2004, 226, 
33–42. 
32.  Messeguer, X.; Escudero, R.; Farre, D.; Nunez, O.; Martinez, J.; Alba, M.M. PROMO: detection 
of known transcription regulatory elements using species-tailored searches. Bioinformatics 2002, 
18, 333–334. 
33.  Farre,  D.;  Roset,  R.;  Huerta,  M.;  Adsuara,  J.E.;  Rosello,  L.;  Alba,  M.M.;  Messeguer,  X. 
Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. 
Nucleic Acids Res. 2003, 31, 3651–3653. 
34.  Chen, J.J.; Li, Z.; Pan, H.; Murphy, D.L.; Tamir, H.; Koepsell, H.; Gershon, M.D. Maintenance of 
serotonin  in  the  intestinal  mucosa  and  ganglia  of  mice  that  lack  the  high-affinity  serotonin 
transporter: Abnormal intestinal motility and the expression of cation transporters. J. Neurosci. 
2001, 21, 6348–6361. 
35.  Coates, M.D.; Mahoney, C.R.; Linden, D.R.; Sampson, J.E.; Chen, J.; Blaszyk, H.; Crowell, M.D.; 
Sharkey,  K.A.;  Gershon,  M.D.;  Mawe,  G.M.;  et  al.  Molecular  defects  in  mucosal  serotonin 
content  and  decreased  serotonin  reuptake  transporter  in  ulcerative  colitis  and  irritable  bowel 
syndrome. Gastroenterology 2004, 126, 1657–1664. 
36.  Houghton, L.A.; Atkinson, W.; Whitaker, R.P.; Whorwell, P.J.; Rimmer, M.J. Increased platelet 
depleted  plasma  5-hydroxytryptamine  concentration  following  meal  ingestion  in  symptomatic 
female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003, 52, 663–670. 
37.  Yeo,  A.;  Boyd,  P.;  Lumsden,  S.;  Saunders,  T.;  Handley,  A.;  Stubbins,  M.;  Knaggs,  A.;  
Asquith, S.; Taylor, I.; Bahari, B.; et al. Association between a functional polymorphism in the 
serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut 
2004, 53, 1452–1458. 
38.  Lim,  J.E.;  Papp,  A.;  Pinsonneault,  J.;  Sadee,  W.;  Saffen,  D.  Allelic  expression  of  serotonin 
transporter (SERT) mRNA in human pons: lack of correlation with the polymorphism SERTLPR. 
Mol. Psychiatry 2006, 11, 649–662. Int. J. Mol. Sci. 2011, 12  6633 
 
 
39.  Philibert,  R.;  Madan,  A.;  Andersen,  A.;  Cadoret,  R.;  Packer,  H.;  Sandhu,  H.  Serotonin  
transporter  mRNA  levels  are  associated  with  the  methylation  of  an  upstream  CpG  island.  
Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B, 101–105. 
40.  Flattem, N.L.; Blakely, R.D. Modified structure of the human serotonin transporter promoter. Mol. 
Psychiatry 2000, 5, 110–115. 
41.  Linden,  D.R.;  White,  S.L.;  Brooks,  E.M.;  Mawe,  G.M.  Novel  promoter  and  alternate  
transcription  start  site  of  the  human  serotonin  reuptake  transporter  in  intestinal  mucosa. 
Neurogastroenterol. Motil. 2009, 21, 534–541, e10–e11. 
42.  Gill, R.K.; Anbazhagan, A.N.; Esmaili, A.; Kumar, A.; Nazir, S.; Malakooti, J.; Alrefai, W.A.; 
Saksena,  S.  Epidermal  growth  factor  upregulates  serotonin  transporter  in  human  intestinal 
epithelial cells via transcriptional mechanisms. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 
300, G627–G636. 
43.  Hu, Y.; Ehli, E.A.; Hudziak, J.J.; Davies, G.E. Berberine and evodiamine influence serotonin 
transporter (5-HTT) expression via the 5-HTT-linked polymorphic region. Pharmacogenomics J. 
2011, doi:10.1038/tpj.2011.24. 
44.  Amin,  Z.;  Canli,  T.;  Epperson,  C.N.  Effect  of  estrogen-serotonin  interactions  on  mood  and 
cognition. Behav. Cogn. Neurosci. Rev. 2005, 4, 43–58. 
45.  Gundlah, C.; Lu, N.Z.; Mirkes, S.J.; Bethea, C.L. Estrogen receptor beta (ERbeta) mRNA and 
protein in serotonin neurons of macaques. Mol. Brain Res. 2001, 91, 14–22. 
46.  Lu, H.; Ozawa, H.; Nishi, M.; Ito, T.; Kawata, M. Serotonergic neurones in the dorsal raphe nucleus 
that project into the medial preoptic area contain oestrogen receptor beta. J. Neuroendocrinol. 2001, 
13, 839–845. 
47.  Alves,  S.E.;  Weiland,  N.G.;  Hayashi,  S.;  McEwen,  B.S.  Immunocytochemical  localization  of 
nuclear  estrogen  receptors  and  progestin  receptors  within  the  rat  dorsal  raphe  nucleus.  
J. Comp. Neurol. 1998, 391, 322–334. 
48.  Mitra,  S.W.;  Hoskin,  E.;  Yudkovitz,  J.;  Pear,  L.;  Wilkinson,  H.A.;  Hayashi,  S.;  Pfaff,  D.W.; 
Ogawa, S.; Rohrer, S.P.; Schaeffer, J.M.; et al. Immunolocalization of estrogen receptor beta in 
the mouse brain: comparison with estrogen receptor alpha. Endocrinology 2003, 144, 2055–2067. 
49.  Arai, N.; Strom, A.; Rafter, J.J.; Gustafsson, J.A. Estrogen receptor beta mRNA in colon cancer 
cells:  growth  effects  of  estrogen  and  genistein.  Biochem.  Biophys.  Res.  Commun.  2000,  270,  
425–431. 
50.  Pfaffl, M.W.; Lange, I.G.; Meyer, H.H. The gastrointestinal tract as target of steroid hormone 
action: quantification of steroid receptor mRNA expression (AR, ERalpha, ERbeta and PR) in  
10 bovine gastrointestinal tract compartments by kinetic RT-PCR. J. Steroid Biochem. Mol. Biol. 
2003, 84, 159–166. 
51.  Di Paolo, T.; Diagle, M.; Picard, V.; Barden, N. Effect of acute and chronic 17 beta-estradiol 
treatment  on  serotonin  and  5-hydroxyindole  acetic  acid  content  of  discrete  brain  nuclei  of 
ovariectomized rat. Exp. Brain Res. 1983, 51, 73–76. 
52.  Morissette, M.; Levesque, D.; Belanger, A.; Di Paolo, T. A physiological dose of estradiol with 
progesterone affects striatum biogenic amines. Can. J. Physiol. Pharmacol. 1990, 68, 1520–1526. Int. J. Mol. Sci. 2011, 12  6634 
 
 
53.  Lu, N.Z.; Eshleman, A.J.; Janowsky, A.; Bethea, C.L. Ovarian steroid regulation of serotonin 
reuptake  transporter  (SERT)  binding,  distribution,  and  function  in  female  macaques.  
Mol. Psychiatry 2003, 8, 353–360. 
54.  Krajnak,  K.;  Rosewell,  K.L.;  Duncan,  M.J.;  Wise,  P.M.  Aging,  estradiol  and  time  of  day 
differentially affect serotonin transporter binding in the central nervous system of female rats. 
Brain Res. 2003, 990, 87–94. 
55.  Bertrand, P.P.; Paranavitane, U.T.; Chavez, C.; Gogos, A.; Jones, M.; van den Buuse, M. The 
effect of low estrogen state on serotonin transporter function in mouse hippocampus: A behavioral 
and electrochemical study. Brain Res. 2005, 1064, 10–20. 
56.  Gundlah, C.; Lu, N.Z.; Bethea, C.L. Ovarian steroid regulation of monoamine oxidase-A and -B 
mRNAs in the macaque dorsal raphe and hypothalamic nuclei. Psychopharmacology 2002, 160, 
271–282. 
57.  Luine,  V.N.;  Khylchevskaya,  R.I.;  McEwen,  B.S.  Effect  of  gonadal  steroids  on  activities  of 
monoamine oxidase and choline acetylase in rat brain. Brain Res. 1975, 86, 293–306. 
58.  Summer, B.E.; Fink, G. Estrogen increases the density of 5-hydroxytryptamine(2A) receptors in 
cerebral cortex and nucleus accumbens in the female rat. J. Steroid Biochem. Mol. Biol. 1995, 54, 
15–20. 
59.  Cyr, M.; Bosse, R.; Di Paolo, T. Gonadal hormones modulate 5-hydroxytryptamine2A receptors: 
emphasis on the rat frontal cortex. Neuroscience 1998, 83, 829–836. 
60.  Tencomnao, T.; Yu, R.K.; Kapitonov, D. Characterization of the human UDP-galactose:ceramide 
galactosyltransferase gene promoter. Biochim. Biophys. Acta 2001, 1517, 416–423. 
61.  Tencomnao, T.; Kapitonov, D.; Bieberich, E.; Yu, R.K. Transcriptional regulation of the human 
UDP-galactose:ceramide  galactosyltransferase  (hCGT)  gene  expression:  functional  role  of  
GC-box and CRE. Glycoconj. J. 2004, 20, 339–351. 
62.  Kubota, N.; Kiuchi, Y.; Nemoto, M.; Oyamada, H.; Ohno, M.; Funahashi, H.; Shioda, S.; Oguchi, K. 
Regulation  of  serotonin  transporter  gene  expression  in  human  glial  cells  by  growth  factors.  
Eur. J. Pharmacol. 2001, 417, 69–76. 
63.  Torrego,  A.;  Pujols,  L.;  Roca-Ferrer,  J.;  Mullol,  J.;  Xaubet,  A.;  Picado,  C.  Glucocorticoid  
receptor  isoforms  alpha  and  beta  in  in  vitro  cytokine-induced  glucocorticoid  insensitivity.  
Am. J. Respir. Crit. Care Med. 2004, 170, 420–425. 
64.  You,  H.J.;  Kim,  J.Y.;  Jeong,  H.G.  17  beta-estradiol  increases  inducible  nitric  oxide  synthase 
expression in macrophages. Biochem. Biophys. Res. Commun. 2003, 303, 1129–1134. 
65.  Hu, L.H.; Chen, F.H.; Li, Y.R.; Wang, L. Real-time determination of human telomerase reverse 
transcriptase mRNA in gastric cancer. World J. Gastroenterol. 2004, 10, 3514–3517. 
66.  Fisker, S.; Hansen, B.; Fuglsang, J.; Kristensen, K.; Ovesen, P.; Orskov, H.; Jorgensen, J.O. Gene 
expression  of  the  GH  receptor  in  subcutaneous  and  intraabdominal  fat  in  healthy  females: 
Relationship to GH-binding protein. Eur. J. Endocrinol. 2004, 150, 773–777. 
©  2011  by  the  authors;  licensee  MDPI,  Basel,  Switzerland.  This  article  is  an  open  access  article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 